-
Most Popular
Search Results
240 results for icgn
Ocugen Investors Are Betting On a Horse Than Can’t Win the Race
OCGN stock has declined to a level where a bounce is certainly possible, but not likely as Ocugen fails to demonstrate any profitability.
Ocugen Needs More Than Covaxin to Boost Its Falling Shares
A doomed-looking vaccine partnership puts Ocugen back in the business of obscurity and OCGN stock at risk of much lower prices.
Anticipation of Better Vaccine News Could Drive Ocugen Higher
From a December low of 29 cents, OCGN stock now trades at about $11, a return of over 3600%. Not bad for a name that…
Ocugen Stock: The Two What-If Scenarios To Consider
OCGN stock is now facing an all or nothing business development and is at a very critical stage so it is wise to avoid it.
Apple News: The New Racially Diverse Emoji Are Here (in Beta)
Apple’s new racially diverse emoji are available in its newest iOS 8.3 beta and they include six different skin tones to represent races.
OCGN Stock: 3 Key Catalysts That Could Send This Stock Soaring Again
Investors in OCGN stock have seen shares settle down quite a bit of late, but there’s room to be optimistic with this biotech stock.
Prepare for Another Pop to $15 With Ocugen Stock
Even while Ocugen changes up its strategy in the U.S., the company is pushing for approval elsewhere and OCGN stock can still move higher.
Ocugen Stock Is Well-Positioned, But Investors Want Results
The company’s latest business update sounds all fine and good, but OCGN stock holders want to see some action, not just words.
OCGN Stock Plunges After WHO Delays Decision on COVAXIN Vaccine
OCGN stock is capping off a day full of gains with a finish in the red. Late afternoon misfortune caused the stock to tank in…
Ocugen Stock Has Way More Downside, Even After This Deep Correction
OCGN stock looks unattractive even after a big correction from highs. Vaccine space looks crowded in the U.S. and Ocugen might not benefit.
Sell Ocugen Stock Before the Other Shoe Finally Drops
The bad news with Covaxin hasn’t sunk in yet with OCGN stock investors, so get out while the stock still remains elevated.
A New Orphan Drug Designation Gives Hope to Ocugen Stock
The FDA just gave a special designation to one of Ocugen’s flagship products. That is good for science and it’s great for OCGN stock.
Volatile Ocugen Stock Is an Incredibly Risky Covid-19 Vaccine Play
The bear case for OCGN stock is more compelling, given the scant details surrounding the Indian Covid-19 vaccine it seeks to commercialize.
Ocugen Now Relies Solely on a Continued Covid-19 Crisis
OCGN stock is a mix of irrational exuberance related to its valuation, unrealistic hopes, continuous speculation and very poor fundamentals.
Is Approval Even Enough for Ocugen Stock?
Ocugen’s partner has shown promise with its Covid-19 vaccine. But with Ocugen getting just 45% of U.S. profits, that promise is priced into OCGN stock.
Ocugen Should Hit $9 If Its Covid-19 Vaccine Gets Approved
Ocugen still hopes its Covid-19 vaccine gets approved to start making revenue. OCGN-stock could be worth as much as $9.09 or 19% over today’s price…
If You Want to Roll the Dice on Ocugen Stock, Understand the Game You’re Playing
In this crazy Reddit-driven stock market, it’s still important to understand why OCGN stock is hot. And why it’s dangerous.
Ocugen Could Still Be Undervalued If Its Covid-19 Vaccine Gets OK
Ocugen could still be undervalued if the FDA approves its Covid-19 vaccine. OCGN could be worth as much as $12.73 per share, 24% higher, using…
Ocugen Stock Looks Like a Really Good Short Candidate Here
There’s a good deal of downside risk, but Ocugen is worth a look. OCGN stock is likely to fall as Ocugen raises $30 million or…
This Is No Time to Be Speculating on Ocugen
Ocugen’s ambitions are not gaining traction in an environment where most biotech investors are focusing on Covid-19. Thus, the case for OCGN stock is unusually…
Ocugen Stock Is Nothing More than a Risky Trade on Even-riskier Biotech
Ocugen gave rise to OCGN stock through a reverse merger with Histogenics. But despite this confusing deal, it really didn’t do much for either company…
7 – 10 of 240 results
